Highest-materiality recent filing
Pure Bioscience raises $1.0M in private placement at $0.0553/share; directors invest
Closed private placement of 18,131,096 shares at $0.0553/share for $1.0M gross.
PURE Bioscience Q2 revenue up 13% to $443K; net loss narrows; USDA cert for PURE Clean
Net product sales Q2 $443K (up 13% YoY); six-month sales $1.15M (up 22% YoY).
PURE Bioscience Q3 net product sales up 11% YoY; net loss narrows to $580K
Net product sales $489K in fiscal Q3 ended Apr 30, 2025, up from $440K YoY.
PURE Bioscience Q2 net sales up 20% YoY to $391K; net loss narrows to $798K
Net product sales $391K for fiscal Q2 ended Jan 31, 2025, vs $325K a year ago (+20%).
PURE Bioscience reports FY 2024 net loss of $3.4M; product sales up 4.5% to $1.955M
Net product sales $1.955M in FY 2024 vs $1.871M in FY 2023, up $84K (4.5%).
Pure Bioscience secures up to $3M in convertible notes; initial $500k from director Tom Y. Lee
Initial tranche of $500,000 convertible promissory note placed with director Tom Y. Lee (affiliates).
Pure Bioscience raises $500K via convertible notes from director; up to $3M total
Initial $500,000 private placement of convertible promissory notes to accredited investors, including board member Tom Y. Lee.
PURE Bioscience Q2 net product sales $325K, net loss $1.0M; shifting to distributor model
Net product sales $325K in Q2 FY2024, down 18% from $396K YoY; net loss $1.002M vs $1.060M.
PURE Bioscience Q1 revenue rises 54% to $718K; net loss narrows to $735K
Net product sales of $718K for Q1 FY2024, up $251K from $467K in Q1 FY2023.
PURE Bioscience reports FY2023 net loss of $4.0M, revenue up slightly; Q4 revenue jumps 49% YoY
Net product sales $1.871M vs $1.813M prior year (+3.2%); net loss widened to $4.0M from $3.5M.
Pure Bioscience raises $1.015M via convertible notes from accredited investors
Issued convertible promissory notes for $1.015M initial principal; potential subsequent closings up to $1.8M total.
Pure Bioscience names Robert Bartlett CEO; Tom Lee resigns, stays on Board
Tom Y. Lee resigned as President and CEO effective March 15, 2023; will continue on Board.
PURE Bioscience Q2 net loss widens to $1.06M; CEO Tom Y. Lee resigns, Robert Bartlett appointed
Q2 net product sales $396K, down ~4.6% YoY; net loss $1.06M vs $702K prior year.
PURE Bioscience FY2022 revenue down 51% to $1.8M; net loss widens to $3.5M
Net product sales of $1.81M vs $3.70M in FY2021; royalties fell to $40K from $229K.
PURE Bioscience raises $3.5M in private placement; CEO and directors participate
Raised $3.5M via private placement of 23,333,332 shares at $0.15/share.
PURE Bioscience Q3 sales down 11% to $497K; nine-month sales fall 50%; net loss widens
Q3 net product sales $497K (-11% YoY); net loss $760K ($0.01 per share).
PURE Bioscience Q2 sales drop 52% to $415K, net loss $702K
Net product sales for Q2 ended Jan 31, 2022 fell 52% to $415K from $868K YoY.
PURE Bioscience Q1 revenue plunges 65% to $497k; net loss widens to $796k
Net product sales $497k, down 65% YoY; net loss $796k vs $180k; EPS $(0.01) vs $(0.00).
PURE Bioscience reports FY2021 net loss of $2.3M; product sales drop 47% YoY
Net product sales $3.698M, down 47% from $6.917M in FY2020.
On May 1, 2024, the Board of Directors (the “Board”) of Pure Bioscience, Inc. (the “Company”) authorized and appointed Darin Zehr, as a member of the Board.
the Board appointed Robert Bartlett, a member of the Board, as the Company’s President and Chief Executive Officer, effective as of the Effective Date.
Tom Myers, the Company’s Chief Operating Officer and member of the Board, resigned as the Company’s Chief Operating Officer in connection with his transition to the Company’s Executive Vice President, Technology and Development, each effective as of the Effective Date.
On March 19, 2023, Kristin A. Taylor delivered notice to the Board of her resignation from the Board, effective March 19, 2023.
Tom Y. Lee, the President, Chief Executive Officer and member of the Board of Directors (the “Board”) of Pure Bioscience, Inc. (the “Company”), resigned as the Company’s President and Chief Executive Officer, effective as of the Effective Date.
Max materiality 0.75 · Median 0.60 · Most common event earnings